Addition of daratumumab to first-line therapy of newly diagnosed multiple myeloma in patients eligible for autologous stem cell transplantation: a single-center real-life experience

Main Article Content

Edoardo Olivari
a:1:{s:5:"en_US";s:19:"University of Milan";}

Keywords

Downloads

Download data is not yet available.


Abstract 267
PDF Downloads 181
HTML Downloads 102

References

1. Moreau, P. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394, 29–38 (2019). https://doi.org/10.1016/S0140-6736(19)31240-1
2. Eleutherakis Papaiakovou, E. et al. Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 64, 2140–2147 (2023). https://doi.org/10.1080/10428194.2023.2253479
3. Cavallaro, G. et al. Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis. Mediterr J Hematol Infect Dis 16, e2024049 (2024). https://doi.org/10.4084/MJHID.2024.049
4. Palumbo, A. et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. Journal of Clinical Oncology 33, 2863–2869 (2015). https://doi.org/10.1200/JCO.2015.61.2267
5. D’Agostino, M. et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology 364, (2022). https://doi.org/10.1200/JCO.21.02614
6. Fernández de Larrea, C. et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J 11, (2021). https://doi.org/10.1038/s41408-021-00587-0
7. Jung, S. H. & Lee, J. J. Update on primary plasma cell leukemia. Blood Res 57, 62 (2022). https://doi.org/10.5045/br.2022.2022033
8. Rah, S. Y. et al. CD38/ADP-ribose/TRPM2-mediated nuclear Ca2+ signaling is essential for hepatic gluconeogenesis in fasting and diabetes. Exp Mol Med 55, 1492–1505 (2023). https://doi.org/10.1038/s12276-023-01034-9

Article Sidebar

PDF HTML
Published
Apr 30, 2025
DOI https://doi.org/10.4084/MJHID.2025.040

Article Details

How to Cite

Olivari, E. (2025) “Addition of daratumumab to first-line therapy of newly diagnosed multiple myeloma in patients eligible for autologous stem cell transplantation: a single-center real-life experience”, Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025040. doi: 10.4084/MJHID.2025.040.
Issue
Vol. 17 No. 1 (2025): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Section
Letters to the Editor
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.